Ionis Pharmaceuticals, Inc. - Common Stock (IONS)

Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.

In two studies, Ionis’ Olezarsen demonstrated a highly statistically significant placebo-adjusted mean reduction in fasting triglycerides of up to 72% at six months.

Ionis posted positive Phase 3 results for olezarsen in severe hypertriglyceridemia, showing 72% triglyceride reduction and 85% fewer pancreatitis events.

The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.

Ionis Pharmaceuticals scored the "bull case" Tuesday after its experimental treatment for high triglycerides beat the placebo.

IONIS Pharmaceuticals (IONS) shows strong technicals with a high setup rating, signaling a potential breakout from its current consolidation pattern.

Takeda stock steadies after early dip as FDA clears Ionis' Dawnzera for hereditary angioedema, posing fresh competition to Takeda's Takhzyro.

FDA approved Ionis' Dawnzera for hereditary angioedema, showing up to 87% attack reduction and strong results in switch patients.

Ionis Pharmaceuticals rose 2.38% after hours following a planned stock sale by its chief scientific officer under a Rule 10b5-1 plan.

Ionis reports surprise Q2 profit, raises 2025 forecast after strong Tryngolza launch and royalty gains push revenue past expectations.

IONIS Pharmaceuticals (NASDAQ:IONS) shows strong technicals with an 8/10 rating and a high-quality setup pattern, making it a breakout candidate for traders.

Biogen's early-stage spinal muscular atrophy drug salanersen showed safety, motor improvements and 70% reduction in neurodegeneration markers after one-year dosing.

Biogen is hoping to top its own spinal muscular atrophy treatment, Spinraza, with a next-generation version.